What Do Karyopharm's Mixed SENTRY Trial Results Mean for Myelofibrosis Treatment

Related Articles

What Do the Povorcitinib Trial Results Mean for Incyte

5 months ago

What Do UNFI's Mixed Q2 Results Really Mean for Investors

5 months ago

What Do the Latest SUMMIT Trial Data Mean for Bezuclastinib

5 months ago

What's Driving Diodes' Recent Surge Despite Mixed Q1 2026 Results

2 months ago

Category

You may also like

Stock News•1 week ago

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Tango Therapeutics' vopimetostat plus daraxonrasib showed an unusually strong early pancreatic-cancer signal in a small, previously treated cohort. A planned front-line Phase 3 trial could expand the ...

TNGX

Share

Stock News•3 weeks ago

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Karyopharm plans to submit an sNDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis under the accelerated approval pathway, based on compelling SVR35 and preliminary overall survival dat...

KPTI

Share

Stock News•3 weeks ago

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics will receive a $20 million milestone payment from partner Takeda after dosing the first patient in the Phase 3 ELRiSE MDS trial of elritercept.

KROS

Share

Stock News•1 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

BMY

Share